Jun 16, 2014 8:30 am EDT SCYNEXIS Provides Update on Corporate Progress and First Quarter 2014 Financial Results
Feb 21, 2014 8:00 am EST SCYNEXIS Receives Qualified Infectious Disease Product (QIDP) Designation from the FDA for Antifungal Agent SCY-078 for Oral Use
Sep 10, 2013 8:20 am EDT SCYNEXIS Signs Deal With R-Pharm to Develop and Market Novel Antifungal Compound in Russia and Other Markets
